<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473651</url>
  </required_header>
  <id_info>
    <org_study_id>18452A</org_study_id>
    <nct_id>NCT04473651</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Lu AG06479 in Healthy Young Men</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Placebo-controlled, Sequential-group, Single-ascending Oral Dose Study Investigating the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of Lu AG06479 and Open-label Cross-over Study to Investigate Intra-subject Variability and Effect of Food in Healthy Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and
      what the body does to Lu AG06479 after swallowing single doses of the drug
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A: randomized, sequential

      Part B: open-label, cross-over
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events (Safety and Tolerability)</measure>
    <time_frame>From baseline to Day 9 (Part A and B)</time_frame>
    <description>Based on the safety assessments (e.g. clinical safety laboratory tests, vital signs, weight and ECG parameters)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0-inf) of Lu AG06479</measure>
    <time_frame>From pre-dose to Day 5 (Part A and B)</time_frame>
    <description>Area under the Lu AG06479 concentration-time curve from time zero to infinity (AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F Lu AG06479</measure>
    <time_frame>From pre-dose to Day 5 (Part A and B)</time_frame>
    <description>Oral clearance of Lu AG06479</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Lu AG06479</measure>
    <time_frame>From pre-dose to Day 5 (Part A and B)</time_frame>
    <description>Maximum observed plasma concentration for Lu AG06479</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: Single dose of Lu AG06479 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Repeated dose of Lu AG06479 and Food interaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence B1: Fed - Fasting- Fasting
Sequence B2: Fasting- Fed - Fasting
Sequence B3: Fasting- Fasting - Fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06479</intervention_name>
    <description>capsules, orally (Part A and B)</description>
    <arm_group_label>Part A: Single dose of Lu AG06479 or Placebo</arm_group_label>
    <arm_group_label>Part B: Repeated dose of Lu AG06479 and Food interaction</arm_group_label>
    <other_name>ABX-1762</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo - capsules, orally (Part A only)</description>
    <arm_group_label>Part A: Single dose of Lu AG06479 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, young, non-smoking men, weight ≥60 kg, and a body mass index (BMI) ≥18.5
             kg/m2 and ≤30 kg/m2 at the Screening Visit.

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Email contact via H. Lundbeck A/S</last_name>
      <email>LundbeckClinicalTrials@Lundbeck.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

